BGLC (BioNexus Gene Lab) Buyback Yield % : 0.00 (As of Apr. 25, 2025)

View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

BioNexus Gene Lab's current buyback yield was 0.00%.

BioNexus Gene Lab Buyback Yield % Historical Data

The historical data trend for BioNexus Gene Lab's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNexus Gene Lab Buyback Yield % Chart

BioNexus Gene Lab Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

-0.09

BioNexus Gene Lab Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioNexus Gene Lab's Buyback Yield %

For the Specialty Chemicals subindustry, BioNexus Gene Lab's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNexus Gene Lab's Buyback Yield % Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

BioNexus Gene Lab Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

BioNexus Gene Lab's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/	5.026209
	=	0.00%

BioNexus Gene Lab's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	0)		/	5.026209
	=	0.00%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

BioNexus Gene Lab Buyback Yield % Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNexus Gene Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

BGLC:USA

Address

No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200

Website

https://www.bionexusgenelab.com

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

Executives

Chak Hua Yew	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong	director, officer: President	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong	officer: Chief Financial Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong	director, officer: Chief Operating Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh	director, officer: Chief Executive Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200